Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis
© Kumar et al. 2008
Received: 28 July 2008
Accepted: 24 November 2008
Published: 24 November 2008
Radiation therapy is generally contraindicated for cancer patients with collagen vascular diseases (CVD) such as scleroderma due to an increased risk of fibrosis. The tight skin (TSK) mouse has skin which, in some respects, mimics that of patients with scleroderma. The skin radiation response of TSK mice has not been previously reported. If TSK mice are shown to have radiation sensitive skin, they may prove to be a useful model to examine the mechanisms underlying skin radiation injury, protection, mitigation and treatment.
The hind limbs of TSK and parental control C57BL/6 mice received a radiation exposure sufficient to cause approximately the same level of acute injury. Endpoints included skin damage scored using a non-linear, semi-quantitative scale and tissue fibrosis assessed by measuring passive leg extension. In addition, TGF-β1 cytokine levels were measured monthly in skin tissue.
Contrary to our expectations, TSK mice were more resistant (i.e. 20%) to radiation than parental control mice. Although acute skin reactions were similar in both mouse strains, radiation injury in TSK mice continued to decrease with time such that several months after radiation there was significantly less skin damage and leg contraction compared to C57BL/6 mice (p < 0.05). Consistent with the expected association of transforming growth factor beta-1 (TGF-β1) with late tissue injury, levels of the cytokine were significantly higher in the skin of the C57BL/6 mouse compared to TSK mouse at all time points (p < 0.05).
TSK mice are not recommended as a model of scleroderma involving radiation injury. The genetic and molecular basis for reduced radiation injury observed in TSK mice warrants further investigation particularly to identify mechanisms capable of reducing tissue fibrosis after radiation injury.
analysis of variance
enzyme-linked immunosorbent assay
TGF-β1 binding protein
latency associated peptide
transforming growth beta 1
tight skin mouse
Radiation fibrosis is frequently seen in patients undergoing high dose curative radiotherapy. It has been described in many tissues, including skin , lung . Interestingly, collagen vascular disease (CVD) patients, particularly with scleroderma, are believed to be at increased risk of developing late complications of fibrosis after radiation therapy [3–6]. The increased toxicity is a serious clinical problem as many of these patients need radiation frequently as a part of cancer treatment and during breast conservation therapy for better cosmesis.
Cytokines, specifically Transforming growth beta 1 (TGF-β1) is considered to play a central role in mediating radiation induced tissue fibrosis . Elevated levels of TGF-β1 have been associated with higher incidence of fibrosis after thoracic and abdomino-pelvic radiotherapy . An abnormal increase in tissue TGF-β1 after radiation may underlie excessive fibrosis seen in CVD patients. Understanding the dynamics of TGF-β1 regulation after radiation in the setting CVD may be helpful in decreasing the long term toxicities associated with radiation therapy.
Tight skin (TSK) mouse has been proposed for use as an experimental animal model for scleroderma [9, 10]. TSK mice display features of dermal fibrosis similar to those found in scleroderma . The TSK phenotype results from duplication of a central portion of the fibrillin-1 gene . Fibrillin-1 (FBN-1) is the major structural protein of connective tissue microfibrils that are key components of elastic fibers. The protein helps stabilize TGF-β in the extracellular matrix  and acts as an extracellular reservoir of growth factors . TSK mutation leads to the production and secretion of a larger mutant FBN-1 protein . The mutant protein expresses an increase in the number of TGF-β binding motifs resulting in more efficient binding of TGF-β . Also the altered FBN-1 containing microfibrils become unstable and undergo proteolysis readily in comparison to wild-type FBN-1 .
Mutations in FBN-1 are associated with various connective tissue disorders in humans including Marfan syndrome (MFS) . Abnormal expression of FBN-1 has also been noted in systemic sclerosis . In the present study, we correlated the TGF-β1 levels with tissue injury and fibrosis seen after radiation in TSK mouse. The results would establish TSK mouse as an animal model for studying radiation induced fibrosis in the setting of scleroderma.
15 mice aged five weeks were exposed to either two fractions of 30 Gy (TSK mice) or two fractions of 25 Gy (C57BL/6 mice) to the hind limbs. The damage to their skin was scored using a semi-quantitative scale. Tissue fibrosis was assessed by measuring passive leg extension.
Male TSK/+ mice, and parental C57BL/6 pa/pa mice (+/+) were obtained from Jackson Laboratory (Bar Harbor, ME). TSK mice are black and are heterozygous for a dominant Fbn1Tsk mutation and a recessive Pldnpa mutation. There is no indication that the recessive Pldnpa mutation contributes to the phenotype of radiation damage.
All experiments performed in this study were approved by and in accordance with the guidelines of the Institutional Animal Care and Use Committee. The mice were kept in individual separate cages under specific pathogen free conditions before and throughout the experiments. This prevents any skin damage that might have been caused by the animals rather than radiation. The animals' health status was checked daily by the scientific investigators, the institutional animal care personnel and reviewed daily with the staff veterinarian. On recommendation by the staff veterinarian, animals were administered topical antibiotic and/or systemic analgesic (Buprenex).
Mice were anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (8 mg/kg). After ten minutes, the animals, as many as ten at a time, were positioned in a plexiglass jig that allowed radiation exposure of the right posterior leg. Shielding was provided with a square primary collimator (12 cm × 12 cm) and a circular secondary Cerrobend collimator (three 1/2 value layers). The dose rate from a 6 MV linear accelerator was 2.5 Gy/min, using 75 cm source to the surface distance. A 2.0 cm tissue equivalent bolus was used to bring the maximal dose to the skin surface. Dose was prescribed to the Dmax and mice received the fractionated schedule (24 hours apart) as indicated for each experiment. Doses were confirmed using micro-TLD dosimetry.
Semi-quantitative Skin damage scores
Minimal erythema, mild dry skin
Moderate erythema, dry skin
Marked erythema, dry desquamation
Dry desquamation, minimal dry crusting
Dry desquamation, dry crusting, superficial minimal scabbing
Patchy moist desquamation, moderate scabbing
Confluent moist desquamation, ulcers, large deep scabs
Open wound, full thickness skin loss
Skin and tissue fibrosis attributable to radiation injury was assessed adopting previously published solid tissue endpoints of damage . At multiple time points from 60 days onward passive leg extension from heel to the medial aspect of the proximal leg (i.e. crotch) was measured with calipers. Skin damage and leg contraction was measured in the same mouse.
Quantitative estimation of TGF-β1 protein level in the skin tissue was done at 0, 30, 60 and 90 days both in radiated and control mice by enzyme-linked immunosorbent assay (ELISA) technique. Skin samples were weighed before being mixed with tissue lysis buffer containing 0.5% Triton X-100, 2 ug/ml Aprotinin in 1× PBS to reach a concentration of 40 mg of tissue/mL of buffer. After homogenization and centrifugation, the supernatant was withdrawn and stored at -80°C until analysis. Analysis was carried out at different time points after radiation for total TGF-β1, as well as for active TGF-β1, with commercially available kits (Promega, Madison, WI). Measurements of active and total amounts of TGF-β1 were performed in separate steps. The active fraction of TGF-β1 was assayed directly in the ELISA plate using the kits provided. For measuring the total amount of TGF-β1, additional samples were acidified to pH 3.0 using 1 mol/L HCl, followed by 15-min incubation at 22°C, resulting in activation of all TGF-β1. To neutralise samples, 1 mol/L NaOH was supplemented before application to the second ELISA plate, according to the manufacturer's instructions. The results were normalized to total protein content based on the method by Lowry using a commercial protein assay (Bio-Rad, Hercules, CA).
Primary tests of significance between TSK and C57BL/6 mice were made for skin injury and leg extension. Skin damage data were not normally distributed. In contrast, leg extension data were normally distributed. Consequently, the medians (and range) for skin damage and the mean (with standard error of the means) for leg extension measurements were employed. A nonparametric median test was applied to the skin damage data to determine the level of significance between TSK and C57BL/6 mice at each of the two radiation doses. A two-way ANOVA test was used for leg extension data to assess the significance between the groups. For TGFβ1 analysis, Student's t test was used to assess the difference between two groups.
Radiation-induced Acute and Chronic Skin Reaction
Radiation-induced Leg Contraction
Measurements of radiation-induced leg contraction in TSK and C57BL/6 mice starting at two months and continuing to the end of the study paralleled the skin injury data. TSK mice receiving 30 Gy × 2 had significantly less leg contraction than C57BL/6 mice receiving 25 Gy × 2 (Fig 1b). The average leg extension at the end of the study period was 8.3 mm in TSK mice compared to an average leg extension of 1.0 mm in the C57BL/6 mice (p < 0.05) (Fig 1b). The average leg extensions at the same time in unirradiated TSK and C57BL/6 were 9.5 mm and 9 mm respectively. The implication is that there was significantly less fibrotic injury in TSK mice (Fig. 1b) compared to C57BL/6 mice.
Analysis of TGF-β1 protein
Collagen vascular disease is clinically considered a relative contraindication for radiation therapy . Scleroderma patients are statistically at higher risk for radiation induced complications in comparison to other collagen vascular disorders [4, 5]. There have been reports of exaggerated cutaneous and internal fibrotic reaction following radiation therapy in scleroderma patients [3, 22]. Consequently, the expectation of radiation response in an experimental model of scleroderma such as TSK mouse is for increased skin damage and fibrosis. But compared to parental C57BL/6 mice, TSK mice showed decreased radiation induced skin injury and fibrosis.
The underlying causes of the fibrotic disorder characteristic of unirradiated TSK mice have been a matter of debate. One probable scenario is based on the observations that increased TGF-β has an established association with increased fibrosis and that the mutated FBN-1 binds more TGF-β than the wild type . In fact, deletion of TGF-β in the heterozygote TSK mouse resulted in less fibrosis . It has been hypothesized that a breakdown of mutant FBN-1 containing unstable microfibrils could lead to a release of sequestered TGF-β which in turn could stimulate fibrosis . Increased TGF-β activity secondary to abnormal FBN-1 leading to increased extracellular matrix deposition has also been hypothesized in initiating the fibrotic process .
The TGF-β family of proteins is synthesized as pro-proteins in association with latency associated peptide (LAP) which keeps the TGF-β in an inactive form . The concentration of biologically active TGF-β is dependent on the conversion from its latent form which requires dissociation from LAP; a process termed latent TGF-β activation. The latent TGF-β binding protein (LTBP) binds latent TGF-β and helps it's targeting to the extracellular matrix . The LTBP interacts with FBN-1 of the microfibrils and stabilize latent TGF-β in the extra cellular matrix . Thus FBN-1 plays a critical role in the activation and signaling of TGF-β.
TGF-β has been implicated in the pathogenesis of diseases such as MFS  and scleroderma [28, 29]. Recently, abnormal FBN-1 has been hypothesized to be the cause aberrant TGF-β signaling in scleroderma . It seems that an altered FBN-1/TGF-β pathway is common to pathogenesis MFS, scleroderma and TSK mouse.
We measured the levels of TGF-β1 in irradiated TSK and C57BL/6 mice skin and correlated them with the level of tissue injury and fibrosis. Both free (active) and total TGF-β1 was higher in C57BL/6 mouse skin at all time points after radiation compared to the TSK mouse and correlated well with the higher degree of skin injury and fibrosis seen in C57BL/6 mouse after radiation. This seems counter intuitive as TSK mice were expected to show greater fibrosis after radiation due to their aberrant TGF-β1 signaling. Similar to TSK mouse, even though dysregulation of TGF-β1 activation secondary to mutation in FBN-1 is implicated in pathogenesis of MFS, patients with MFS apparently tolerate radiation treatment . In contrast, scleroderma patients are known to be at risk of increased fibrosis after radiation therapy.
There may be several possible reasons for the observed results. Tight binding of TGF-β1/LTBP to the abnormal FBN-1 may result in decreased release of the biologically active TGF-β1 in TSK mice after tissue injury. Indeed, radiation is known to induce activation of latent TGF-β1 to its active form in vivo . This seems not to be the case as we observed lower levels of both free and bound TGF-β1 (after acid activation) in the TSK mouse skin compared to C57BL/6 mouse. Alternatively, breakdown of unstable microfibrils could lead depletion of TGF-β1 stores and may blunt TGF-β1 mediated effects including fibrosis after radiation injury. The heterozygote TSK/+ mouse also produces comparable amounts of normal FBN-1 molecule along with larger abnormal FBN-1 molecule . But this doesn't seem to increase the local TGF-β1 availability after radiation injury in TSK mice. It may also be that the abnormal FBN-1 molecule protects TSK mice from radiation induced skin injury by a mechanism not involving TGF-β1.
Based on the data presented, we conclude that the TSK mouse is not a suitable model to study the effects of radiation in case of scleroderma. Further studies are required to elucidate the role of FBN-1 in controlling TGF-β1 signaling in TSK mouse. The underlying mechanism of radiation resistance in TSK mouse can be exploited to prevent long term fibrosis in patients undergoing radiation therapy.
The studies were supported by NIH U19AI067734-010005 (JHK) as part of a Center Grant awarded to John Moulder at The Medical College of Wisconsin.
- Bentzen SM, Thames HD, Overgaard M: Latent-time estimation for late cutaneous and subcutaneous radiation reactions in a single follow-up clinical study. Radiotherapy Oncol 1989, 15: 267–274.View Article
- McDonald S, Rubin P, Phillips TC, Marks LB: Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995, 31: 1187–1203.View ArticlePubMed
- Abu-Shakra M, Lee P: Exaggerated fibrosis in patients with systemic radiation therapy in patients with collagen vascular diseases (scleroderma) following radiation therapy. J Rheumatol 1993, 20: 1601–1603.PubMed
- Phan C, Mindrum M, Silverman C, Paris K, Spanos W: Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003, 9: 461–466.View ArticlePubMed
- Chen AM, Obedian E, Haffty B: Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001, 7: 480–491.PubMed
- Morris MM, Powell SN: Irradiation in the setting of collagen vascular disease: Acute and late complications. J Clin Oncol 1997, 15: 2728–2735.PubMed
- Martin M, Lefaix J, Delanian S: TGF-β1 and radiation fibrosis: A master switch and a specific therapeutic target. Int J Radiat Oncol Biol Phys 2000, 47: 277–290.View ArticlePubMed
- Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL: Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2000, 56: 988–995.View Article
- Green MC, Sweet HO, Bunker LE: Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976, 82: 493–512.PubMed
- Kasturi KN, Shibata S, Muryoi T, Bona CA: Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol 1994, 11: 253–271.View ArticlePubMed
- Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA: Tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6: 300–313.View ArticlePubMed
- Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY: Latent transforming growth factor-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003, 278: 2750–2757.View ArticlePubMed
- Charbonneau NL, Ono RN, Corson GM, Keene DR, Sakai LY: Fine tuning of growth factor signals depends on fibrillin microfibril networks. Birth Defects Res 2004, 72: 37–50.View Article
- Kielty CM, Raghunath M, Siracusa LD, Sherratt MJ, Peters R, Shuttleworth CA, Jimenez SA: The Tight skin Mouse: Demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol 1998, 140: 1159–1166.View ArticlePubMed
- Saito S, Nishimura H, Brumeanu TD, Casares S, Stan AC, Honjo T, Bona CA: Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (TSK) mice. Mol Immunol 1999, 36: 169–176.View ArticlePubMed
- Gayraud B, Keene DR, Sakai LY, Ramirez F: New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse. J Cell Biol 2000, 150: 667–680.View ArticlePubMed
- Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, Palz M, Pregla R, Tiecke F, Rosenberg T: Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 2002, 20: 153–161.View ArticlePubMed
- Tan FK, Stivers DN, Foster MW, Chakraborty R, Howard RF, Milewicz DM, Arnett FC: Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998, 41: 1729–1737.View ArticlePubMed
- Field SB, Law MP: The relationship between early and late radiation damage in rodents' skin. Int J Radiat Biol Relat Stu Phys Chem Med 1976, 30: 557–564.View Article
- Stone HB: Leg contracture in mice: An assay of normal tissue response. Int J Radiat Oncol Biol Phys 1984, 10: 1053–1061.View ArticlePubMed
- Winchester DP, Cox JD, the American College of Radiology, American College of Surgeons, College of American Pathologists, and Society of Surgical Oncology: Standards for diagnosis and management of invasive breast carcinoma. CA Cancer J Clin 1998, 48: 83–107.View ArticlePubMed
- Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA: Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991, 265: 3292–3295.View ArticlePubMed
- McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin 4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001, 116: 136–43.View ArticlePubMed
- Lemaire R, Bayle J, Lafyatis R: Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-b regulation and systemic sclerosis. Curr Opin Rheumatol 2006, 18: 582–7.View ArticlePubMed
- Lawrence DA, Pircher R, Kryceve-Martinerie C, Jullien P: Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984, 121: 184–188.View ArticlePubMed
- Miyazono K, Olofsson A, Colosetti P, Heldin CH: A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta1. Embo J 1991, 10: 1091–1101.PubMed
- Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC: Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33: 407–411.View ArticlePubMed
- Smith EA, LeRoy EC: A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990, 95 (Suppl) : 125–127.View Article
- Falanga V, Julien JM: Observations in the potential role of transforming growth factor-beta in cutaneous fibrosis systemic sclerosis. Ann N Y Acad Sci 1990, 593: 161–171.View ArticlePubMed
- Finlay M, Laperriere N, Bristow RG: Radiotherapy and Marfan syndrome: a report of two cases. Clin Oncol 2005, 17: 54–56.View Article
- Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA: Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994, 93: 892–899.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.